COMPANY PROFILE

BioCryst Pharmaceuticals

BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina

Durham, United StatesFounded 1986Biotech & Life Sciences

Valuation $2.63B Market cap · 2026

Revenue $702M Latest reported FY

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals focuses on developing innovative oral drugs for rare diseases, with a particular emphasis on hereditary angioedema (HAE). The company leverages a combination of traditional cell biology and medicinal chemistry to create synthetic compounds that target specific proteins to combat diseases. BioCryst serves patients suffering from rare conditions, aiming to enhance their ability to engage in everyday activities. Operating in the biopharmaceutical market, BioCryst's business model revolves around research and development, clinical trials, and eventual commercialization of its drug pipeline. Revenue is generated through the sale of approved drugs and potential licensing agreements. The company's commitment to scientific excellence and patient needs drives its mission to deliver extraordinary treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1986
Headquarters: Durham, United States
Listing: IPO 1994
Employees: 617
Open positions: 17
Dealroom signal: 40.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, observatoire healthtech
Business model: Manufacturing
Client focus: b2b
Investment activity: 1 company, latest Oct 2025
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	Apr 2023	$450M	—	Pharmakon Holdings	↗
POST IPO EQUITY✓Other financing	Nov 2021	$350M	—	OMERS Capital Markets · Royalty Pharma	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$702M	-19.7%	−$498M	-70.9%	−$579M	-82.4%	$166M
2025	$875M	+94.1%	$365M	41.7%	$264M	30.2%	$166M
2024	$451M	+36%	$13M	3%	−$89M	-19.7%	$175M
2023	$331M	+22.4%	−$86M	-26%			$217M
2022	$271M	+72.3%	−$143M	-52.9%
2021	$157M	+782.4%	−$178M	-113%
2020	$18M	—	−$165M	-928.2%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

BioCryst Pharmaceuticals website traffic

Latest recorded traffic for BioCryst Pharmaceuticals is 27K monthly website visits, up 17.4% over the last three months. BioCryst Pharmaceuticals's team grew 14.5% over the past year.

Latest monthly visits27K 3-month web change+17.4% 1-year team growth+14.5%

Monthly website visitsApr 2016–Mar 2021

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Sales - Rare Disease Specialist (Hudson Valley, NY)Hudson, New York, United States, Northern America, Americas · Sales · Aug 31, 2026 IT Support Specialist - Onsite Support Operations (Contract)Durham, North Carolina, United States, Northern America, Americas · CSM & Support · Aug 31, 2026 Sr. Payroll Manager4505, Emperor Boulevard, Imperial Center, Durham, Durham County, North Carolina, 27703, United States · Accounting · Aug 30, 2026 VP, Global Clinical Development4505, Emperor Boulevard, Imperial Center, Durham, Durham County, North Carolina, 27703, United States · Other · Aug 28, 2026 Sr. Clinical Data Manager (contract)4505, Emperor Boulevard, Imperial Center, Durham, Durham County, North Carolina, 27703, United States · Data Science & Engineering · Aug 28, 2026 Exec. Director, US Market Access4505, Emperor Boulevard, Imperial Center, Durham, Durham County, North Carolina, 27703, United States · Marketing & Communication · Aug 27, 2026 Sales - Rare Disease Specialist (Detroit)Detroit, Michigan, United States, Northern America, Americas · Sales · Aug 24, 2026 Sales - Rare Disease Specialist (Cleveland)Cleveland, Ohio, United States, Northern America, Americas · Sales · Aug 24, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HBHyphen BiomedIn-vitro diagnostic reagents for thrombosis and hemostasis	Neuville-sur-Oise, France	Operational	71	—	—
TOTollysDevelopment of innovative immunotherapies targeting cancer through the modulation of the TLR3 receptor	Lyon, France	Closed
PHPhost’inA biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors	Montpellier, France	Operational
C2C2CareDesigns therapeutic solutions based on virtual reality in order to immerse patient in an environment that creates a certain stress	Sanary-sur-Mer, France	Operational
AFAelis FarmaBiotech company conducting research and development on innovative signaling specific drugs	Bordeaux, France	Operational
VAValnevaA biotech company developing and commercializing vaccines for infectious diseases with major unmet needs	Saint-Herblain, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
TTTreeFrog TherapeuticsStem cell company that will enable millions of patients to access the medical revolution of cell	Pessac, France	Operational